Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis.

@article{Coisne2009CuttingEN,
  title={Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis.},
  author={Caroline Coisne and Wenxian Mao and Britta Engelhardt},
  journal={Journal of immunology},
  year={2009},
  volume={182 10},
  pages={5909-13}
}
The humanized anti-alpha(4) integrin Ab Natalizumab is an effective treatment for relapsing-remitting multiple sclerosis. Natalizumab is thought to exert its therapeutic efficacy by blocking the alpha(4) integrin-mediated binding of circulating immune cells to the blood-brain barrier (BBB). As alpha(4) integrins control other immunological processes, natalizumab may, however, execute its beneficial effects elsewhere. By means of intravital microscopy we demonstrate that natalizumab specifically… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 47 extracted citations

ALCAM (CD166) is involved in extravasation of monocytes rather than T cells across the blood-brain barrier.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism • 2017
View 5 Excerpts

Similar Papers

Loading similar papers…